Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.29 USD
Change Today -0.12 / -8.51%
Volume 847.7K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1129 North McDowell Boulevard

Petaluma, CA 94954

United States

Phone: 707-283-0550

Fax: 707-283-0551

Oculus Innovative Sciences, Inc., a specialty device and pharmaceutical company, develops, produces, and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States and internationally. The company’s key proprietary technology, Microcyn, is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. These pathogens include viruses, fungi, spores and bacteria, including antibiotic-resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE), as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. Various Microcyn Technology advanced tissue care products are designed to treat infections and enhance healing while reducing the need for antibiotics. The company obtained 11 clearances from the U.S. Food and Drug Administration (FDA) that permit it to sell its Microcyn-based products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States. Outside of the United Sates, the company sells products for dermatological and advanced tissue care with a European Conformity marking (known as Conformite Europeenne or CE) covering 10 of its products, 14 approvals from the Mexican Ministry of Health, and various approvals in Central America, China, Southeast Asia, and the Middle East. Microcyn Technology’s ability to reduce the need for antibiotics through prevention and treatment of infections while promoting wound healing is based on its engineered chemistry. As a result of the company’s patented manufacturing process, Microcyn is a proprietary solution of oxychlorine compounds that interact with and inactivate surface proteins on cell walls and membranes of microorganisms. The functions of these proteins are varied and play major roles in cell communication, nutrient and waste transport and other required functions for cell viability. Once Microcyn surrounds single cell microorganisms, it damages these proteins, causing the cell membrane to rupture, leading to cell death. The company has completed a proof-of-concept Phase II trial in the United States, which demonstrated the effectiveness of Microcyn Technology in mildly infected diabetic foot ulcers with the primary endpoint of clinical cure and improvement of infection. Products Microcyn Skin and Wound Care with Preservatives: Management of wounds via debridement of wounds such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites. Microcyn Skin & Wound HydroGel: Used on first and second degree burns, exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers, and for the management of mechanically or surgically debrided wounds. Alevicyn Dermal Spray: Cleansing, irrigation, moistening, debridement and removal of foreign material, including microorganisms and debris from exudating wounds, acute and chronic dermal lesions, including stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted/donor sites and exit sites. Alevicyn Antipuritic Gel: Management of itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Celacyn Prescription Scar Management Gel: Management of old and new hypertrophic and keloid scarring on scars resulting from burns, general surgical procedures, and trauma wounds. MicrocynAH Hydrogel and Wound And Skin Care Products: Management of animal wounds, such as hot spots, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin, and lacerations. Microdacyn Antiseptic: Wound care antiseptic. Baby Microdacyn: Treatment of diaper rash and rosaduras in children. Gramaderm Solution: Used as an adjunct in the tropical treatment of mild to moderate acne. Gramaderm Gel: Used as an adjunct in the tropical treatment of mild to moderate

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $1.29 USD -0.12

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,980 JPY +5.00
Henry Schein Inc $146.28 USD -0.51
Integra LifeSciences Holdings Corp $62.04 USD -2.04
Patterson Cos Inc $49.77 USD -0.18
Smith & Nephew PLC 1,197 GBp +3.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit www.oculusis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.